Eloxatin
information and resources from the National Cancer Institute
Eloxatin
(Other name for: oxaliplatin)
Eloxatin
(Other name for: oxaliplatin)
oxaliplatin
Accel. Approv. (clinical benefit not established) in combination with infusional 5-FU/LV, is indicated for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/LV and irinotecan.
Sanofi Synthelabo Aug 09 2002
|
|
|
|
news articles
Debiopharm SA Invests in Nanocarrier Mezzanine Funding Round Mar 30, 2006
Yahoo! News (press release) Debiopharm has developed and registered three products with combined sales in excess of $2.2bn in 2005: Eloxatin®, one of sanofi-aventis' leading marketed ...
Tomudex® Plus Eloxatin® Effective in Gemzar®-Resistant ... Mar 24, 2006
Cancer Consultants (press release), ...metastatic pancreatic cancer who have failed Gemzar (gemcitabine) based regimens benefit from treatment with Tomudex (raltitrexed) and Eloxatin (oxaliplatin). ...
Tomudex® Plus Eloxatin® Effective in Gemzar®-Resistant ... Mar 23, 2006
Cancer Consultants (press release), ...to an article recently published in the British Journal of Cancer, treatment consisting of Tomudex® (raltitrexed) and Eloxatin® (oxaliplatin) provides ...
Pt used in pancreatic cancer treatment - 27th March 2006 Mar 27, 2006
Platinum today, Researchers found that the use of Tomudex (raltitrexed) and Eloxatin (oxaliplatin) yielded results in half of those patients who had failed to respond to ...
Erbitux® Plus Camptosar® Effective in Patients with Colorectal ... Mar 29, 2006
Cancer Consultants (press release), Patients were considered to be heavily pre-treated and had cancer that had progressed following prior therapies, including Eloxatin® (oxaliplatin) and ...
Health council urges NIS 466m. expansion of services Mar 29, 2006
Jerusalem Post, ...slow-release insulins such as Lantus, Levemir, Humalog, Apidra and Novorapid (for diabetics, eliminating previous restrictions); Eloxatin for stage III ...
Patients Of UK's Second Biggest Killer To Gain Access To ... Feb 28, 2006
Medical News Today (press release), NICE) published their Final Appraisal Determination (FAD), which advocates the use of the potentially life-saving treatment Eloxatin (oxaliplatin) in ...
Sanofi-Aventis' Battered Charm Mar 1, 2006
BusinessWeek Key brands, such as Plavix, Taxotere and Eloxatin oncology treatments, Lantus antidiabetes agent, and Avapro -- an antihypertensive -- will likely drive the ...
Genta Incorporated Announces Fourth Quarter and Year End 2005 ... Mar 10, 2006
PR Newswire (press release), Most recently, Mr. Sanders was Vice-President, Oncology Sales, at sanofi-aventis, where he led the Eloxatin(R), Taxotere(R), and ELITEK(R) sales teams. ...
Debiopharm SA and Dyax Corp. Restructure Development Agreement for ... 21 Dec 2005
PR Newswire (press release), Debiopharm has developed and registered three products with combined sales in excess of $1.8bn in 2004: Eloxatin(R), one of sanofi-aventis' leading marketed ...
Xeloda®/Eloxatin®/Avastin® (XeloxA) Highly Active in Newly ... Nov 18, 2005
Cancer Consultants (press release), ...remission rate for patients with metastatic colorectal cancer following treatment with treatment with Xeloda (capecitabine) and Eloxatin (oxapliatin) and ...
Hospital cancer drug funding approved Dec 18, 2005
Scoop.co.nz (press release), ...metastatic colorectal cancer. The change will see oxaliplatin (Eloxatin) made available as a first-line treatment. PHARMAC Medical ...
Pharma Reformulates Dec 5, 2005
Chemical & Engineering News ...for non-Hodgkin's lymphoma; Novartis' Gleevec for chronic myeloid leukemia and gastrointestinal stromal tumors (GISTs); Sanofi-Aventis' Eloxatin, licensed from ...
|
|
